It appears you are describing a chemical compound with a very specific structure, but there's a slight issue with the naming:
* **Epoxy is not a standard IUPAC prefix.** It's usually used to indicate the presence of an epoxide group (a three-membered ring containing an oxygen atom). However, it's unclear where the epoxide group is located in your description.
* **1,2-dihydroxy suggests two hydroxyl groups (OH) attached to positions 1 and 2.** But again, we need to be specific about the positions in the chrysene molecule.
**To understand this compound and its importance, we need a more precise structural description.**
Here's how you can provide a more accurate description:
1. **Provide the full IUPAC name:** If you have the full name, that would be the most accurate way to describe the compound.
2. **Draw the chemical structure:** This is the most unambiguous way to define the compound. You can use a chemical drawing program or a simple drawing tool to illustrate the molecule.
3. **Specify the position of the epoxide group:** Indicate the carbon atoms forming the epoxide ring.
**Once we have a clear understanding of the compound's structure, we can discuss its significance for research.**
**Here are some potential reasons why a compound like this might be important for research:**
* **Potential biological activity:** Many chrysene derivatives have shown biological activity, including anti-cancer, anti-inflammatory, and antioxidant properties. The specific arrangement of functional groups (hydroxyl, epoxide) might influence these activities.
* **Synthetic target:** The compound might be a synthetic target for the development of new drugs or materials.
* **Environmental impact:** Some chrysene derivatives are known to be pollutants. Understanding their reactivity and degradation pathways is important for environmental research.
**To get a more complete answer, please provide more specific information about the compound.**
1,2-dihydroxy-epoxy-1,2,3,4-tetrahydro-5-methylchrysene: 5-methyl group increases its carcinogenic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 57139 |
| MeSH ID | M0114096 |
| Synonym |
|---|
| 5-methylchrysene-1s,2r-diol-3r,4s-epoxide |
| chryseno(3,4-b)oxirene-1,2-diol, 1,2,2a,3a-tetrahydro-4-methyl-, (1s,2r,2ar,3as)- |
| trans-1,2-dihydroxy-syn-3,4-epoxy-1,2,3,4-tetrahydro-5-methylchrysene |
| (-)-anti-1(s),2(4)-dihydroxy-3(r),4(s)-epoxy-1,2,3,4-tetrahydro-5-methylchrysene |
| ccris 2086 |
| chryseno(3,4-b)oxirene-1,2-diol, 1,2,2a,3a-tetrahydro-4-methyl-, (1-alpha,2-beta,2a-alpha,3a-alpha)- |
| 1,2-dihydroxy-epoxy-1,2,3,4-tetrahydro-5-methylchrysene |
| chryseno(3,4-b)oxirene-1,2-diol, 1,2,2a,3a-tetrahydro-4-methyl-, (1r,2s,2as,3ar)-rel- |
| (1alpha,2beta,2aalpha,3aalpha)-1,2,2a,3a-tetrahydro-4-methylchryseno(3,4-b)oxirene-1,2-diol |
| anti-(+-)-trans-1,2,3,4-tetrahydro-5-methylchrysene-1,2-diol-3,4-epoxide |
| anti-5-methylchrysene-1,2-diol-3,4-epoxide |
| chrysene-1,2-diol, 1,2,3,4-tetrahydro-3,4-epoxy-5-methyl-, (1s-(1-alpha,2-beta,3-beta,4-beta))- |
| ccris 1750 |
| 111901-40-7 |
| 5-methylchrysene-1,2-dihydrodiol-3,4-epoxide |
| 5-methylchrysene-1,2-diol-3,4-epoxide |
| 5-methyl-1,2-dihydroxy-3,4-epoxy-1,2,3,4-tetrahydrochrysene |
| anti-5-methylchrysene-1,2-dihydrodiol-3,4-epoxide |
| 81851-68-5 |
| anti-(+/-)-trans-1,2,3,4-tetrahydro-5-methylchrysene-1,2-diol-3,4-epoxide |
| (3s,5r,6r,7s)-19-methyl-4-oxapentacyclo[9.8.0.02,8.03,5.012,17]nonadeca-1(11),2(8),9,12,14,16,18-heptaene-6,7-diol |
| DTXSID401033682 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (36.00) | 18.7374 |
| 1990's | 11 (44.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 1 (4.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 28 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||